Skip to main content
SpringerLink
Log in

Cellular and Molecular Biology

PSA screening in high-risk groups: what are the changes in benefits and harm?

  • Correspondence
  • Published:
British Journal of Cancer Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McHugh J, Saunders EJ, Dadaev T, McGrowder E, Bancroft E, Kote-Jarai Z, et al. Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups. Br J Cancer. 2022;126:1366–73. https://doi.org/10.1038/s41416-021-01669-3

    Article  PubMed  Google Scholar 

  2. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:1901–13. https://doi.org/10.1001/jama.2018.3710

    Article  Google Scholar 

  3. Takahashi T. Would you play a Russian Roulette-type game of prostate-specific antigen screening on yourself? Eur Urol. 2022;81:e22.

    Article  Google Scholar 

  4. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15:e234–42. https://doi.org/10.1016/S1470-2045(13)70598-9

    Article  PubMed  PubMed Central  Google Scholar 

  5. Young RH, Eble JN. The history of urologic pathology: an overview. Histopathology. 2019;74:184–212.

    Article  Google Scholar 

  6. Totten RS. Some experiences with latent carcinoma of the prostate. Bull N Y Acad Med. 1953;29:579–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Aronowitz R. "Screening" for prostate cancer in New York’s skid row: history and implications. Am J Public Health. 2014;104:70–6.

    Article  Google Scholar 

  8. Humphrey PA. Histopathology of prostate cancer. Cold Spring Harb Perspect Med. 2017;7:a030411.

    Article  Google Scholar 

  9. Studer UE, Hauri D, Hanselmann S, Chollet D, Leisinger HJ, Gasser T, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol. 2004;22:4109–18. https://doi.org/10.1200/JCO.2004.11.514

    Article  PubMed  Google Scholar 

  10. Schellhammer PF. A urologist’s personal view of prostate cancer. Turk J Urol. 2016;42:121–6. https://doi.org/10.5152/tud.2016.50318.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health and Welfare Bureau, Kitakyushu City Office, Jyonai 1-1, Kitakyushu, 803-8501, Japan

    Takeshi Takahashi

Authors
  1. Takeshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Takahashi.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takahashi, T. PSA screening in high-risk groups: what are the changes in benefits and harm?. Br J Cancer 127, 1173–1174 (2022). https://doi.org/10.1038/s41416-022-01947-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-022-01947-8

  • Springer Nature Limited

This article is cited by

Search

Navigation